Specifically, YAP activation is associated with reduced patient survival in CRC, NSCLC, HCC, ovarian cancer, esophageal squamous cell carcinoma, and urothelial carcinoma of the bladder [60-63,74,86,87]. The gene discussed is YAP1; the disease is ovarian carcinoma.